Abstract | Anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) affects systemic small vessels and is accompanied by the presence of ANCAs in the serum. This disease entity includes microscopic polyangiitis, granulomatosis with polyangiitis, eosinophilic granulomatosis with polyangiitis and drug-induced AAV. Similar to other autoimmune diseases, AAV develops in patients with a predisposing genetic background who have been exposed to causative environmental factors. The mechanism by which ANCAs cause vasculitis involves ANCA-mediated excessive activation of neutrophils that subsequently release inflammatory cytokines, reactive oxygen species and lytic enzymes. In addition, this excessive activation of neutrophils by ANCAs induces formation of neutrophil extracellular traps (NETs). Although NETs are essential elements in innate immunity , excessive NET formation is harmful to small vessels. Moreover, NETs are involved not only in ANCA-mediated vascular injury but also in the production of ANCAs themselves. Therefore, a vicious cycle of NET formation and ANCA production is considered to be involved in the pathogenesis of AAV. In addition to this role of NETs in AAV, some other important discoveries have been made in the past few years. Incorporating these new insights into our understanding of the pathogenesis of AAV is needed to fully understand and ultimately overcome this disease.
1
), ANCA-associated vasculitis (AAV) was established as a disease entity distinct from other vasculitides. AAV is now recognized as a systemic vasculitis of small vessels that is accompanied by the presence of ANCAs in the serum. The major antigens targeted by these ANCAs are myeloperoxidase (MPO) and proteinase 3 (PR3; also known as myeloblastin).
AAV includes microscopic polyangiitis (MPA), granulomatosis with polyangiitis (GPA), eosinophilic granulomatosis with polyangiitis (EGPA) and drug-induced AAV 2 . MPA affects systemic small vessels -preferentially those of the renal glomeruli -and the majority of patients with MPA are positive for MPO-ANCAs 2 . The characteristic histopathological feature of MPA is necrotizing vasculitis; granulomatous inflammation is generally absent 2 . By contrast, GPA is characterized by granulomatous inflammation with necrosis that usually involves the respiratory tract and the simultaneous development of necrotizing small-vessel vasculitis 2 . Typically, patients with GPA are positive for PR3-ANCAs 2 . Pauciimmune necrotizing and crescentic glomerulonephritis (NCGN) is associated with both MPA and GPA 2 . EGPA is an eosinophil-rich necrotizing vasculitis with a granulomatous reaction that predominantly affects small-to-medium-sized vessels 2 . This disease is associated with adult-onset asthma and allergic sinusitis; high numbers of eosinophils in peripheral blood and affected tissues are its essential feature. About 50% of patients with EGPA are positive for MPO-ANCAs 2 . Finally, drugs such as propylthiouracil (an anti-thyroid drug), hydralazine (an anti-hypertension drug) and cocaine can induce production of ANCAs and lead to the development of drug-induced AAV 2 . Epidemiological studies have revealed ethnic differences in both ANCA specificity and manifestations of AAV [3] [4] [5] [6] . For example, PR3-ANCAs and GPA are most common in Western countries, whereas MPO-ANCAs and MPA predominate in East Asian countries (including Japan) [3] [4] [5] [6] . International collaborative groups have published guidelines for diagnosis 7, 8 and treatments aimed at remission induction 9, 10 and maintenance of remission of AAV 11 . Although these efforts have resulted in a remarkable improvement in the prognosis of affected patients, more work is needed to fully understand and ultimately overcome AAV. Therefore, in this Review, we present an updated understanding of the aetiology and pathogenesis of AAV.
Pathogenesis and therapeutic interventions for ANCA-associated vasculitis

Aetiology
Genetic factors
Genome-wide association studies (GWASs) [12] [13] [14] have identified several genes involved in either susceptibility or resistance to AAV (Table 1) . Among these, the strongest associations with AAV are displayed by major histocompatibility complex class II (MHC II) genes. A GWAS of a European population demonstrated that GPA with PR3-ANCAs is most strongly associated with the HLA-DP region and that MPA with MPO-ANCAs is highly associated with the HLA-DQ region 12 . Interestingly, these data also indicated that the HLA genomic signature was associated with ANCA specificity (that is, PR3-ANCAs or MPO-ANCAs) rather than with the clinical manifestation (GPA or MPA). A GWAS of a North American population also found that the HLA-DP locus had the strongest association with GPA 13 . That study further identified HLA-DPB1*04 as a risk allele for GPA. By contrast, HLA-DRB1*09:01, which is common in East Asian but rare in European populations, is strongly associated with MPA (MPO-ANCAs) in the Japanese population 15 . These ethnic differences in MHC II allele frequencies reflect the epidemiological differences observed in AAV; that is, the predominance of GPA with PR3-ANCAs in white European populations and the predominance of MPA with MPO-ANCAs in Asian populations 3 . Non-MHC genes identified as associated with AAV include PTPN22 (encoding tyrosine-protein phosphatase non-receptor type 22) 16 , SERPINA1 (encoding α1-antitrypsin), PRTN3 (encoding PR3) and SEMA6A (encoding semaphorin 6a) [12] [13] [14] . The frequency of a gainof-function single-nucleotide polymorphism (SNP) in PTPN22 is higher in white patients with AAV than in the general American white population 16 . This variant increases the activity of PTPN22, which negatively regulates the production of IL-10 (an immuno suppressive cytokine), resulting in hyper-responsiveness of the immune system in patients with AAV 16 . A SNP near SERPINA1 is associated with resistance to GPA (PR3-ANCA) 17 . Because α1-antitrypsin is an inhibitor of PR3, this SNP might affect the function of PR3. 17 A SNP in PRTN3 is associated with resistance to PR3-ANCA AAV 12 , whereas a SNP in SEMA6A is associated with resistance to GPA 13, 14 . Future studies are expected to reveal how these molecules are involved in the pathogenesis of AAV.
Epigenetic factors
Epigenetic modifications, including trimethylation of histone 3 lysine 27 (H3K27me3) and DNA methylation, are implicated in the regulation of MPO and PRTN3 gene expression 18, 19 . Reduced H3K27me3 is associated with aberrant expression of MPO and PRTN3 genes in patients with active AAV 18 . The levels of MPO and PRTN3 promoter methylation are negatively correlated with the number of mRNA transcripts of these genes 19 . Moreover, MPO and PRTN3 promoter methylation is reduced in patients with active AAV and is increased during remission of AAV 19 . Elevated expression of MPO and PR3, mediated by these epigenetic modifications, is also linked with AAV 19 .
Environmental factors
Environmental factors that can trigger the development of AAV include infectious agents, drugs (such as propylthiouracil, hydralazine and cocaine), and airborne particulates such as silica dust. For example, toxic shock syndrome toxin 1, which is secreted by Staphylococcus aureus, is a risk factor for disease relapse in GPA 20 . Although the association of silica with AAV has been intensely debated, a systematic review and meta-analysis confirmed the association between silica dust exposure and development of AAV 21 . Moreover, morbidity and disease severity increased substantially in patients with AAV after the great earthquakes in Japan (Hanshin-Awaji in 1995 (ref. 22 ) and East Japan in 2011 (ref. 23 )). These observations suggest that silica dust in the air, caused by the massive destruction and subsequent reconstruction of the cities 22 and by the marine sludge and sediments deposited in the subsequent tsunami disaster 23 , might have affected the presentation of AAV, especially its respiratory manifestations such as pulmonary haemorrhage and interstitial pneumonitis. However, in a contrasting study, no difference in the incidence of AAV was observed before versus after the February 2011 earthquake in Christchurch, New Zealand 24 . Therefore, whether environmental pollution from earthquakes can affect the incidence or presentation of AAV remains unresolved.
Anti-neutrophil cytoplasmic antibodies
The two major types of ANCAs have different cellular localization patterns, which can be detected by indirect immunofluorescence of ethanol-fixed neutrophils. One type of ANCA is associated with staining around the nucleus and is known as perinuclear ANCA (p-ANCA), whereas the other type is associated with diffuse staining of the cytoplasm and is known as cytoplasmic ANCA (c-ANCA). The major antigen targeted by p-ANCA is MPO and that targeted by c-ANCA is PR3. At present, ANCAs are usually detected quantitatively by enzymelinked immunosorbent assay (ELISA) using plates coated with these antigens. ANCAs detected by ELISA are called MPO-ANCAs or PR3-ANCAs according to the target antigen used.
In addition to MPO and PR3, several other neutrophil-derived molecules can be targeted by ANCAs, including α-enolase, azurocidin, bactericidal permeability-increasing protein (BPI), cathepsin G,
Key points
• Anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAv) affects systemic small vessels and is accompanied by the presence of ANCAs in the serum.
• AAv includes microscopic polyangiitis (mPA), granulomatosis with polyangiitis (GPA), eosinophilic granulomatosis with polyangiitis (eGPA) and drug-induced AAv.
• AAv can develop in patients with a genetically predisposing background who are exposed to causative environmental factors, such as infectious agents, drugs and air pollutants.
• ANCAs have a central role in the pathogenesis of AAv because they induce excessive activation of neutrophils, which results in injury to small vessels.
• Other immune cells (such as dendritic cells, macrophages, B cells and T cells), the complement system and humoral factors are also involved in the pathogenesis of AAv.
• elucidation of the aetiology and pathogenesis of AAv is needed to develop new biomarkers as well as novel targeted therapeutic agents.
www.nature.com/nrrheum elastase, defensin, lactoferrin, lysosome-associated membrane glycoprotein 2 (LAMP2) and moesin [25] [26] [27] [28] [29] [30] [31] [32] . The pathogenicity of these 'minor' ANCAs is generally low, and p-ANCAs other than MPO-ANCAs are not usually associated with vasculitis; however, discussion is ongoing as to whether some minor ANCAs are involved in the pathogenesis of AAV [25] [26] [27] [28] [29] [30] [31] [32] .
Mechanisms of anti-neutrophil cytoplasmic antibody production. Disordered regulation of neutrophil extracellular traps (NETs) is known to contribute to ANCA production. Although NETs are an element of the innate immune system that is essential for host defence 33 , the formation and breakdown of NETs is strictly regulated because excessive exposure to NETs can cause angiopathy 34, 35 . NETs are degraded mainly by DNase I in serum 36 ; however, the administration of propylthiouracil produces abnormal NETs that are resistant to degradation by DNase I and thus can persist in vivo 37 . Tolerance to MPO present in these NETs is thereafter broken, resulting in MPO-ANCA production. Of interest, MPO-ANCAs are produced in ~30% of patients treated with propylthiouracil 38 . The molecular modification of MPO induced by propylthiouracil -a change in the protein structure surrounding the haem iron from a rhombic to an axial form 39 -could contribute to the breakdown of tolerance to MPO 37 . In mice, the injection of a mixture of myeloid dendritic cells and neutrophils that have formed NETs induces ANCA production, whereas the injection of a mixture of myeloid dendritic cells and DNase-I-treated NET-forming neutrophils does not induce ANCA production 40 . This finding suggests that the DNA in NETs is required for MPO-ANCA and PR3-ANCA formation. The DNA in NETs can also activate B cells via Toll-like receptor 9 to accelerate antibody production 41 . In summary, several steps are involved in the process of ANCA production. During NET formation, the contents of neutrophilic granules, including MPO and PR3, are mixed with chromatin fibres and bind to DNA, which might modify the antigenicity of these autoantigens 40 . This physiological first step is not specific to patients with AAV. The second step is the incomplete degradation of NETs, which seems to be specific to some autoimmune diseases. Although NETs are appropriately degraded by serum DNase I under physiological conditions 36 , NET degradation is reduced in patients with AAV 42 as well as in patients with systemic lupus erythematosus 36 . The third step is antigen presentation. Susceptibility to AAV is strongly associated with specific MHC II genotypes 12, 13, 15 . Therefore, patients who express MHC II molecules that are apt to present MPO or PR3 are those most likely to produce ANCAs. This phenomenon could be specific to patients with AAV. Misfolded MPO presented by MPA-susceptible class II MHC (HLA-DR) can also be a target of ANCAs 43 . These misfolded MPO proteins are transported to the cell surface (via a chaperone-like function of HLA-DR), where cryptic epitopes of MPO are recognized by the immune system 43 .
Pathogenicity of anti-neutrophil cytoplasmic antibodies.
Several animal models of AAV have been established, including passive immune models [44] [45] [46] [47] [48] , active immune models [49] [50] [51] [52] [53] , drug-induced models 37, 54 , molecular mimicry models 27 and spontaneous models 55 . The characteristics of these models are summarized in Supplementary  Tables 1-3 . Studies in these models have shown that ANCAs not only serve as a biomarker of AAV but also have pathogenic potential themselves. For example, injection of either MPO-ANCAs (obtained by the immunization of MPO-deficient mice with mouse MPO) or splenocytes from such immunized mice into immunocompromised or wild-type mice can induce NCGN 44 . In other animal models, such as Wistar-Kyoto rats immunized with human MPO, the anti-human MPO antibodies generated cross-react with rat MPO, resulting in the development of NCGN and pulmonary haemorrhage 49 . These animal models clearly indicate the pathogenicity of ANCAs.
The mechanism by which ANCAs cause vasculitis has been explained as follows 56 . Pro-inflammatory cytokines such as TNF and IL-1β are generated during infection and activate neutrophils, which then express target antigens (namely, MPO and PR3) on their cell surface. ANCAs bind to these antigens. At the same time, the crystallizable fragment (Fc) portion of these ANCAs binds to Fcγ receptors on neutrophils, inducing excessive activation of the neutrophils. This hyperactivation results in abnormal cytokine production accompanied by the release of reactive oxygen species (ROS) and lytic enzymes, which injure vascular endothelial cells 57, 58 . The excessive activation of neutrophils elicited by ANCAs also induces the formation of NETs 42, 59 . Moreover, humoral factors other than ANCAs, such as damage-associated molecular patterns, are involved in the formation of NETs in patients with AAV 60 . This excessive NET formation -specifically, exposure to NET components such as histones and matrix metalloproteinases (MMPs) -is harmful to vascular endothelial cells 34, 35, 56 . Despite the critical role of ANCAs in the pathogenesis of AAV, the histological hallmark of AAV is necrotizing glomerulonephritis without apparent deposition of immune complexes (pauci-immune glomerulonephritis). Of interest, when TNF-primed neutrophils were exposed to ANCAs in vitro, the ANCAs disappeared after AAV, anti-neutrophil-cytoplasmic-antibody-associated vasculitis; GPA , granulomatosis with polyangiitis; MPA , microscopic polyangiitis; MPO, myeloperoxidase; PR3, proteinase 3.
NAtuRe Reviews | RhEuMATOlOGy induction of NETs owing to their digestion by neutrophil elastase derived from NET-forming neutrophils 61 . These findings suggest that NETs contribute to the disappearance of immunoglobulins from AAV lesions. Immunofluorescence studies can detect NETs in the necrotizing lesions of AAV by the presence of citrullinated histones accompanied by extracellular DNA 59, [62] [63] [64] . In addition, in our own unpublished research, we have found scattering of citrullinated histones, in a manner that cannot be explained by an intracellular distribution, in vessels affected by AAV ( fig. 1) . Interestingly, almost no NET deposition can be detected in the lesions of ANCA-unrelated necrotizing vasculitis, such as polyarteritis nodosa (PAN).
Association of anti-neutrophil cytoplasmic antibodies with disease activity. Although AAV is an ANCAassociated disease, ANCA titres do not necessarily reflect disease activity except for renal involvement 65 . The lack of correlation between ANCA titres and vasculitic disease activity can be explained by differences in the epitopes and affinity of ANCAs. MPO is a 158 kDa heterotetrameric glycoprotein consisting of two light chains (14 kDa each), two heavy chains (59 kDa each) and two haem molecules 66 . ANCAs in patients with MPO-AAV typically recognize an epitope at the amino terminus of the MPO heavy chain 67, 68 ; this specificity is most likely in patients with the most severe disease activity. MPO-ANCAs are subdivided into high-affinity and low-affinity antibodies 69 . Vasculitic disease activity is higher in patients with high-affinity MPO-ANCAs than in those with low-affinity MPO-ANCAs 42, 69 . In patients with low vasculitic disease activity despite high MPO-ANCA titres, the MPO-ANCAs might target epitopes located in a low-risk region, instead of at the amino terminus of the MPO heavy chain, or the MPO-ANCAs might have low antigen affinity.
ANCAs cannot be detected in some patients with clinical manifestations of MPO-AAV. In some of these patients, laboratory tests for ANCAs can give falsenegative results because 50 kDa fragments of ceruloplasmin bind to the ANCAs in the serum 70 . However, the clinical relevance of the production of ceruloplasmin degradation products in vivo remains unclear.
Pathogenesis
The pathogenesis of AAV partially overlaps between MPA, GPA, EGPA and drug-induced AAV. Of these, MPA is considered the prototypic AAV because the pathways involved in its pathogenesis ( fig. 2) are actually shared by all types of AAV. Accordingly, the discussion of common pathways below, although particularly relevant to MPA, also applies to the other subtypes of AAV. Macrophages stimulated by IL-17 A produce pro-inflammatory cytokines, such as TNF and IL-1β, which prime neutrophils. At the same time, C5a generated by activation of the alternative complement pathway binds to the C5a receptor on the surface of neutrophils, which also primes neutrophils. Meanwhile, neutrophils stimulated by bacteria form neutrophil extracellular traps (NETs). In patients with low NET degradation activity , these NETs persist, and prolonged exposure to their contents disrupts tolerance to specific self-antigens, notably myeloperoxidase (MPO) and proteinase 3 (PR3). These antigens are presented to CD4 + T cells by dendritic cells, resulting in production of anti-neutrophil cytoplasmic antibodies (ANCAs). Primed neutrophils express MPO and PR3 on their plasma membrane, to which PR3-ANCAs and MPO-ANCAs bind; at the same time, the crystallizable fragment (Fc) region of these ANCAs binds to the Fcγ receptor on neutrophils. This binding induces excessive activation of neutrophils, leading to abnormal cytokine production accompanied by the release of reactive oxygen species (ROS) and lytic enzymes, and further NET formation, which injures vascular endothelial cells. Humoral factors other than ANCAs, such as damage-associated molecular patterns (DAMPs), are also involved in NET formation in patients with ANCA-associated vasculitis (AAV). The major angiopathic molecules in NETs are histones dissociated from DNA and matrix metalloproteinases (MMPs) such as MMP2 and MMP9. Both B cell-activating factor (BAFF, also known as B lymphocyte stimulator (BLyS) or TNF ligand superfamily member 13B), which is produced by activated neutrophils, and CD4 + T cells (via IL-21) stimulate B cells. This process enables continuous ANCA production. TGFβ, transforming growth factor-β. differentiation of naive T cells into T helper 17 (T H 17) cells 71 . IL-17 (which is released from T H 17 cells stimulated by dendritic-cell-derived IL-23) can induce the release of pro-inflammatory cytokines, such as TNF and IL-1β, from macrophages 72 . These pro-inflammatory cytokines prime neutrophils.
Common pathways
Disturbed T cell immune homeostasis is critically involved in both this priming and subsequent processes. For example, functional and numerical abnormalities of regulatory T (T reg ) cells, which suppress the proliferation of autoreactive T cells, are associated with the development of AAV 73 . In patients with AAV, a proportion of T reg cells differentiate into T H 17 cells, resulting in increased production of IL-17A (ref. The complement system is also involved in priming of neutrophils; accordingly, the role of complement proteins in the pathogenesis of MPO-AAV has been studied in mouse models. C4-deficient mice injected with MPOANCAs also develop vasculitis, as do wild-type mice injected with MPO-ANCAs; however, mice deficient in both C5 and factor B do not develop vasculitis after the injection of MPO-ANCAs 75 . This finding suggests that the alternative complement pathway is involved in the pathogenesis of MPO-AAV. Interestingly, injection of MPO-ANCAs into C6-deficient mice also results in vasculitis; therefore, an alternative pathway mechanism that is not mediated by the membrane attack complex (MAC) is likely to contribute to the development of MPO-AAV 76 . Neutrophil priming by C5a -an activated C5 fragment -is one such mechanism that deserves further consideration 56 . Binding of C5a to its receptor on the neutrophil cell surface induces neutrophil activation and ANCAmediated glomerulonephritis in mice 77 . In addition, the C5a-induced release of tissue factor from neutrophils can promote hypercoagulability in patients with AAV 78 . Furthermore, elevated serum levels of C3a and C5a, which suggest activation of the alternative complement pathway and neutrophil priming via the C5a receptor, have been demonstrated in patients with active AAV 79, 80 . MPO-ANCA production. When stimulated by bacteria neutrophils form NETs, which are then degraded by various enzymes, the most important of which (in serum) is DNase I 36 . Serum DNase I activity is markedly lower in patients with MPA than in healthy individuals 42 . In patients with MPA who have low NET degradation activity, NETs persist in vivo and tolerance to MPO is disrupted, resulting in MPO-ANCA production 81 . The structural modification of MPO proteins 39 contributes to this mechanism because these modified proteins can be recognized as neoantigens.
Dendritic cells are involved in the presentation of MPO contained in NETs to CD4 + T cells 40 . These CD4 + T cells induce the differentiation of B cells into plasma cells that produce MPO-ANCAs via the production of IL-21 (ref.
82
). TNF ligand superfamily member 13B (also known as B cell-activating factor (BAFF) or B lymphocyte stimulator (BLyS)) released from activated neutrophils is also involved in the activation of B cells 82 .
Excessive activation of neutrophils. Primed neutrophils express ANCA-specific antigens on their plasma membrane. ANCAs bind to these antigens and, at the same time, the Fc region of ANCAs binds to the Fcγ receptor on neutrophils. This binding induces excessive activation of these neutrophils, leading to abnormal cytokine production, the release of ROS and lytic enzymes, and eventually NET formation [57] [58] [59] 83 . The most important angiopathic molecules in NETs are histones dissociated from DNA and MMPs such as MMP2 and MMP9 (refs 34,35,56 ). Together, these data indicate that a vicious cycle of NET and ANCA formation is involved in the pathogenesis of AAV (fig. 3) .
Semaphorin 4D regulates neutrophil activation in small vessels, and impairment of this regulation has been demonstrated to lead to NET-mediated vascular injury 84, 85 . Serum levels of soluble semaphorin 4D are elevated in patients with AAV and correlate with disease activity 84, 85 . The same researchers also found that the cell-surface expression of semaphorin 4D is decreased in neutrophils from patients with AAV as a consequence of the proteolytic cleavage of membrane semaphorin 4D 84, 85 . Interestingly, membranous semaphorin 4D on neutrophils binds to plexin B2 on vascular endothelial cells, and this interaction decreases NET formation 84, 85 . Collectively, these findings suggest that a physiological mechanism that inhibits NET formation in small vessels is impaired in patients with AAV and that this impairment is associated with increased NET formation.
Some researchers have found that serum levels of NETs do not correlate with either AAV disease activity 86 or ANCA titres 60, 87 . However, a gold-standard method for quantifying NETs in vivo has not yet been established 88 ; therefore, future studies are needed to define the association between NETs and AAV.
Granulomatosis with polyangiitis
Neutrophil priming and ANCA-mediated excessive activation of neutrophils also occur in GPA, similarly to MPA. However, necrotizing granulomas in the respiratory tract and PR3-ANCA production are distinct features of GPA.
Necrotizing granuloma formation. The mechanism of necrotizing granuloma formation is thought to involve infection, possibly by Staphylococcus aureus, which activates tissue-resident macrophages in the bronchial epithelium via Toll-like receptors 89 . These macrophages release pro-inflammatory cytokines, including TNF and IL-1β, which promote recruitment of neutrophils and monocytes from the blood into the developing lesion. Recruited neutrophils that encounter microorganisms release ROS and lytic enzymes and undergo lysis, resulting in the formation of the necrotic core of the lesion 89 . The recruited monocytes differentiate into macrophages that secrete IL-23, resulting in the differentiation of T cells towards a T H 17 phenotype. IL-17 released from T H 17 cells is critically implicated in formation of the granuloma that surrounds the necrotic region 89 .
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PR3 on the surface of apoptotic neutrophils interferes with the induction of anti-inflammatory mechanisms following phagocytosis of these cells by macrophages 90 . In mouse models, concomitant injection of PR3-ANCAs and PR3-expressing apoptotic neutrophils induced a T H 17 response, revealing a GPA-specific mechanism of immune polarization 91 . Furthermore, levels of IL-17 and IL-23 are increased during active disease in patients with GPA 92 . Effector memory T cells, the proliferation of which is dependent on IL-15, also contribute to granuloma formation in patients with GPA 93 . PR3-stimulated dendritic cells derived from patients with GPA induced a higher IFNγ response in PR3-specific CD4 + T cells than did PR3-stimulated dendritic cells from healthy individuals 94 . This T H 1-type response might favour granuloma formation in patients with GPA.
PR3-ANCA production. MPO-ANCAs and PR3-ANCAs seem to share a fundamental underlying mechanism of production. Indeed, both types of ANCA are produced when mice are injected with NETs and myeloid dendritic cells 40 . The major factor that affects ANCA specificity seems to be the MHC II genotype, although other factors are specific to the production of each type of ANCA. For example, a complementary PR3-mediated mechanism has been specifically implicated in the production of PR3-ANCAs in GPA 95 . The initial immune response in GPA has been identified as directed against complementary PR3 transcripts, after which PR3-ANCAs develop during a secondary anti-idiotypic immune response 95 . Interestingly, pathogens such as S. aureus have genetic sequences that are complementary to the human PRTN3 gene, which encodes PR3; thus, this observation suggests that the complementary PR3 transcripts have an exogenous origin. In support of this notion, chronic carriage of S. aureus in the nasal cavity increases the risk of relapse of GPA 96 . EGPA EGPA is characterized by allergic manifestations such as adult-onset asthma and sinusitis. Eosinophilia and a prominent infiltration of eosinophils into vasculitic lesions are distinct features of EGPA. About 50% of patients with EGPA are positive for MPO-ANCAs, and the presence of these autoantibodies shows a positive correlation with renal involvement but an inverse correlation with cardiac involvement 97 . Interestingly, the prevalence of ANCAs in patients with EGPA decreases over time 98 .
Eosinophilia and infiltration of eosinophils.
EGPA is regarded as a T H 2-cytokine-mediated disease because elevated levels of T H 2 cytokines (such as IL-4, IL-5 and IL-13) are associated with eosinophilia in patients with EGPA 99 . C-C motif chemokine 26 (CCL26; also known as eotaxin 3) released from vascular endothelial cells is implicated in the tissue infiltration of eosinophils 100 . The tissue-infiltrating eosinophils secrete eosinophilic granules, including eosinophilic neurotoxin, major basic proteins and eosinophilic cationic proteins, resulting in tissue destruction 101 . Although eosinophil peroxidase shares 68% amino acid identity with neutrophil MPO 102 , the mechanism of MPO-ANCA production in patients with EGPA remains to be identified.
Persistence of NETs
Excessive NET formation Anti-lactoferrin antibody in EGPA. Anti-lactoferrin antibodies (one of the 'minor' ANCAs) are present in a subgroup of patients with EGPA but not in patients with MPA or GPA 32 . The frequency of renal involvement, serum C-reactive protein levels and disease activity are all considerably higher in anti-lactoferrin-antibodypositive than in anti-lactoferrin-antibody-negative patients with EGPA. Lactoferrin is present in neutrophilspecific granules and is immediately secreted (via degranulation) upon their activation. Lactoferrin is an endogenous suppressor of NET formation 103 ; thus, anti-lactoferrin antibodies inhibit the NET-suppressing activity of lactoferrin and consequently promote NET formation after activation of neutrophils 32 . Therefore, the presence of anti-lactoferrin antibodies is thought to be associated with NET-related disease activity in patients with EGPA.
Drug-induced AAV
Many drugs, such as propylthiouracil, benzylthiouracil, methimazole, carbimazole, minocycline, cefotaxime, nitrofurantoin, d -penicillamine, hydralazine, allopurinol, levamisole, phenytoin, sulfasalazine, rifampicin, anti-TNF agents and cocaine, can induce AAV 104, 105 . Although several different pathways might lead to the development of drug-induced AAV, the innate and adaptive immune responses share some common mechanisms.
Propylthiouracil treatment induces the formation of DNase-I-resistant NETs 37 . Because propylthiouracil does not inhibit DNase I activity directly, metabolites of propylthiouracil are hypothesized to mask the DNase I recognition sites in DNA extruded in NETs 37 . Cocaine and levamisole induce the formation of NETs enriched in neutrophil elastase and, potentially, in mitochondrial DNA, which is highly inflammatory 106 . Hydralazine also increases NET formation 107 , and NETs induced by these drugs or reagents could be a source of antigens leading to ANCA formation. Some drugs, such as hydralazine, induce promoter demethylation of DNA in T cells, resulting in their activation 107 . Activated T cells contribute to autoantibody production by B cells and plasma cells.
Therapeutic targets in AAV
International collaborative studies led to the publication of treatment guidelines for both remission induction 9,10 and maintenance of remission 11 . Although these efforts have resulted in a remarkable improvement in the prognosis of patients with AAV, development of therapies that target cells and molecules specifically involved in the pathogenesis of AAV is needed to ultimately overcome this disease. In the following sections, we focus on the therapeutic possibilities inspired by discoveries in the pathogenesis of AAV made in the past 5 years (Table 2) .
Targeting B cells
BAFF is produced by neutrophils in large amounts and has an important role in B cell survival. Serum levels of this molecule increase with progression of AAV 108, 109 . A clinical trial of combination therapy with methotrexate plus the BAFF antagonist blisibimod had promising results 110 . Bortezomib inhibits proteasomes, which have an essential role in the intracellular clearance of unwanted peptides. Treatment with bortezomib results in depletion of antibody-producing plasma cells. In a mouse model, bortezomib treatment led to a reduction in MPO-AAV disease activity as a result of the deletion of MPO-ANCA-producing plasma cells 111 . In humans, bortezomib treatment ameliorates disease activity in patients with refractory AAV 112 .
Targeting T cells
Cytotoxic lymphocyte antigen 4 (CTLA4), which is expressed specifically and constitutively on T reg cells, also has an important role in the regulation of self-tolerance. Abatacept, a selective co-stimulation inhibitor, is a soluble fusion protein composed of the Fc region of human IgG1 linked to the extracellular domain of CTLA4. This agent binds to CD80 or CD86 on the surface of antigenpresenting cells, thereby inhibiting T cell activation. A clinical study has demonstrated that abatacept treatment is well tolerated and associated with a high frequency of disease remission in patients with relapsing GPA 113 . The results of a double-blind randomized controlled trial of abatacept as first-line therapy for AAV (ABAVAS) 114 are expected to be released soon.
Targeting cytokines
Patients with AAV can develop high levels of circulating cytokines. Serum levels of pro-inflammatory cytokines, particularly TNF and IL-6, are much higher in patients with AAV than in healthy individuals 115, 116 . Serum levels of IL-6 are also substantially increased in patients with active MPA and GPA 115, 116 . Thus, treatment with anticytokine biologic agents has been studied in patients with these diseases.
Although conflicting reports have been published on the efficacy of TNF blockade in patients with AAV (reviewed elsewhere 117 ), IL-6 blockade seems to be a promising approach. IL-6 not only promotes B cell differentiation but also has a central role in macrophage activation, T cell differentiation, plasma cell survival and induction of other cytokines. Tocilizumab, a humanized anti-IL-6 receptor antibody, achieved a complete and sustained remission in one patient with MPA who did not respond to standard immunotherapy 118 . However, large-scale clinical studies are required to define the adverse events associated with anti-IL-6 therapy and to establish the long-term prognosis of treated patients. NA , not applicable.
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IL-5 binds to the IL-5 receptor, which leads to the growth of B cells and activation of eosinophils. A clinical study has demonstrated that ~50% of patients with EGPA treated with the anti-IL-5 antibody mepolizumab will enter remission 119 .
Targeting the complement system
The complement system is presumed to be crucial for the development of AAV. C5a, a product derived from activation of the alternative complement pathway, is thought to be a major neutrophil-activating molecule 120 . In mice, treatment with C5 and C5a receptor-inhibiting antibodies suppresses the development of MPO-AAV 76, 121 . The C5a receptor antagonist avacopan blocks C5a-mediated neutrophil activation and infiltration into the vascular endothelium. A clinical study of avacopan in patients with AAV demonstrated the therapeutic potency of this treatment, which was capable of replacing glucocorticoids 122 . A larger clinical trial (ADVOCATE) 123 is underway that will Investigate the efficacy of this drug in patients with AAV.
Targeting humoral factors
Not only pathogenic ANCAs but also other humoral factors are involved in the pathogenesis of AAV. Some clinical studies have demonstrated that plasma exchange, which removes these factors, improves renal dysfunction in patients with AAV and shortens the duration of hospitalization 124, 125 . A clinical trial of plasma exchange and glucocorticoids (a cornerstone of AAV treatment 126 ) in patients with AAV (PEXIVAS) 127 has been completed and analysis of the results is now ongoing.
Conclusions
Thorough investigations into the genetic and environmental factors associated with AAV; ANCA pathogenicity; and the roles of neutrophils, other immune cells and humoral factors in the pathogenesis of AAV have led to several breakthroughs in the understanding and treatment of this disease. Consequently, promising new therapeutic agents that target B cells, T cells and cytokines have been developed. However, no therapies have yet been developed that specifically target neutrophils, the pivotal contributors to this disease (although glucocorticoids do prolong neutrophil survival) 124 . Future strategies should specifically address the role of neutrophils in AAV. Finally, C5 and C5a receptor inhibitors could become promising treatments for AAV, and NET inhibitors (if they can be developed) might also be potently effective. In the meantime, continued collaborative studies as well as basic and clinical research are needed to fully understand the aetiology and pathogenesis of AAV and ultimately to develop safe and effective treatments.
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